Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Foà

Showing results (81-90 of 529) with videos related to

Pageof 53
Sort By:
American Journal of Hematology|September 30, 2017
Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-lifeMassimo Breccia, Gioia Colafigli, Matteo Molica, et al.
British Journal of Haematology|July 6, 2017
Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitorsMatteo Molica, Martina Canichella, Gioia Colafigli, et al.
Expert Review of Hematology|September 3, 2020
The advantages and risks of ruxolitinib for the treatment of polycythemia veraGioia Colafigli, Emilia Scalzulli, Sara Pepe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformationSabina Chiaretti, Xiaochun Li, Robert Gentleman, et al.
Advances in Therapy|October 7, 2017
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical ExperienceGilles Salles, Martin Barrett, Robin Foà, et al.
Annals of Hematology|May 29, 2018
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular eventsMatteo Molica, Emilia Scalzulli, Gioia Colafigli, et al.
American Journal of Hematology|September 24, 2017
The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trialsMatteo Molica, Martina Canichella, Danilo Alunni Fegatelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosisLuciana Teofili, Fiorina Giona, Maurizio Martini, et al.
Expert Review of Anticancer Therapy|July 5, 2018
Current and future therapeutic approaches for the treatment of follicular lymphomaAlessandro Pulsoni, Luca Vincenzo Cappelli, Laura Ballotta, et al.
Haematologica|December 11, 2013
FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysisMassimo Breccia, Giuseppina Loglisci, Maria Giovanna Loglisci, et al.
Pageof 53

Showing results (81-90 of 529) with videos related to

Sort By:
Pageof 53
American Journal of Hematology|September 30, 2017
Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-lifeMassimo Breccia, Gioia Colafigli, Matteo Molica, et al.
British Journal of Haematology|July 6, 2017
Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitorsMatteo Molica, Martina Canichella, Gioia Colafigli, et al.
Expert Review of Hematology|September 3, 2020
The advantages and risks of ruxolitinib for the treatment of polycythemia veraGioia Colafigli, Emilia Scalzulli, Sara Pepe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformationSabina Chiaretti, Xiaochun Li, Robert Gentleman, et al.
Advances in Therapy|October 7, 2017
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical ExperienceGilles Salles, Martin Barrett, Robin Foà, et al.
Annals of Hematology|May 29, 2018
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular eventsMatteo Molica, Emilia Scalzulli, Gioia Colafigli, et al.
American Journal of Hematology|September 24, 2017
The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trialsMatteo Molica, Martina Canichella, Danilo Alunni Fegatelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosisLuciana Teofili, Fiorina Giona, Maurizio Martini, et al.
Expert Review of Anticancer Therapy|July 5, 2018
Current and future therapeutic approaches for the treatment of follicular lymphomaAlessandro Pulsoni, Luca Vincenzo Cappelli, Laura Ballotta, et al.
Haematologica|December 11, 2013
FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysisMassimo Breccia, Giuseppina Loglisci, Maria Giovanna Loglisci, et al.
Pageof 53